Trial Profile
A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors ReXceptor
- 12 Aug 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2014 New trial record